Home
About Us
Core Team
Development History
Corporate Culture
S&T
Research Areas
Technology Platforms
Research and Development
Marketed Products
R&D Products
R&D Pipeline
Academic Progress
Blog
Company News
Media Reports
Join Us
Post-Doctoral Center
Contact Us
Media News
2024-11-28
Good news! Nivolumab's indication for head and neck tumors has been added to the National Medical Insurance Catalog.
2024-11-19
CCTV's "Finance & Business Live": Biotech Pharma Leverages Biotechnology to Enhance Public Health
2024-11-04
From environmental science to biomedicine, leveraging the power of technology to ignite new hope in cancer treatment.
2024-06-04
[Breaking News] Long-term Follow-up Results of a Randomized Phase III Study Comparing Nivolumab Plus Chemoradiotherapy to Chemoradiotherapy Alone for Locally Advanced Head and Neck Squamous Cell Carcinoma
2024-06-03
[Breaking News] ASCO Annual Meeting Unveils Three Studies on Nivolumab Combined with Concurrent Chemoradiotherapy for Locally Advanced Cervical Squamous Cell Carcinoma
2024-05-28
Biotech Pharma participates in the "YiQi Cup" 2024 Economic Development Zone Foreign-Invested Enterprises Staff Table Tennis Tournament